BioSpace News Archive

Today, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.

Masimo announced the findings of a prospective, randomized study published in Perioperative Medicine in which Dr. Yu Wang and colleagues at institutions in Shenzhen, Shaoguan, and Guangzhou, China evaluated the use of noninvasive, continuous Masimo PVi®, as part of goal-directed fluid therapy, to guide intraoperative fluid administration during gastrointestinal surgery on elderly patients by comparing it to conventional fluid therapy.

Abivax SA announced that it has concurrently signed two structured debt financing transactions for a total amount of up to EUR 150M consisting of up to EUR 75M from Kreos Capital and Claret European Growth Capital together with the issuance of warrants exercisable to receive up to EUR 8M worth of ordinary shares of the Company, par value of EUR 0.01 per share, and up to EUR 75M from a fund advised by Heights Capital Management, Inc..

Porosome Therapeutics, Inc. is the first company with a technology platform that develops novel therapies targeting the porosome, the universal cellular structure controlling secretion.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.

Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended June 30, 2023.

Carina Biotech (Carina), a cell therapy immuno-oncology company, announced a poster presentation from preclinical studies of its LGR5-targeting CAR-T platform in colorectal cancer at the 8th CAR-TCR Summit that will take place in Boston, Massachusetts from 29 August – 1 September 2023.

Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today, announced that Dr. Boro Dropulić, CEO, will speak at the 8th CAR-TCR Summit taking place at the Hynes Convention Center in Boston, MA from August 29-September 1, 2023.

Enveric Biosciences today announced that it has completed manufacturing of drug material enabling the completion of preclinical work for EB-373 including all bioanalytical method validation, GLP toxicology and GLP safety pharmacology studies.